33 results on '"Katlinskaya, Yuliya"'
Search Results
2. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia
3. Supplementary Information from A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon
4. Spatial characterization and quantification of CD40 expression across cancer types
5. Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study
6. Additional file 1 of Spatial characterization and quantification of CD40 expression across cancer types
7. Additional file 2 of Spatial characterization and quantification of CD40 expression across cancer types
8. Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL
9. Abstract P260: Development and validation of a novel T-cell modulating, microbiome-based peptide for combination with immunotherapy
10. Safety and Efficacy of Subcutaneous (SC) Blinatumomab for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
11. Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury
12. Abstract B28: A novel intestinal microbiome-derived peptide modulates immune cell activity and the tumor microenvironment
13. Soluble human CXCR2: Structure, properties, bioactivity
14. Human soluble CXCR2 in health and disease
15. Enzyme-linked immunoassays differentially recognizing glycosylated and deglycosylated forms of soluble human CXCR2
16. Abstract 1490: Novel microbiome-derived peptides activate the host innate immune system by regulation of TLR signaling
17. Abstract 4963: A novel intestinal microbiome-derived peptide modulates immune cell activity and the tumor microenvironment
18. Abstract 576: A novel intestinal microbiome-derived peptide modulates host T cell activation
19. An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles
20. Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments
21. Abstract 1637: ICOS agonism induces potent immune activation and anti-tumor response in non-clinical models
22. A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon
23. Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment
24. PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma
25. Abstract A63: IFNAR1 downregulation during melanoma progression upregulates αv expression and promotes metastasis
26. Type I Interferons Control Proliferation and Function of the Intestinal Epithelium
27. Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression
28. Type 1 interferons contribute to the clearance of senescent cell
29. DNA-Damage-Induced Type I Interferon Promotes Senescence and Inhibits Stem Cell Function
30. Type I Interferon Controls Propagation of Long Interspersed Element-1
31. Triggering ubiquitination of IFNAR 1 protects tissues from inflammatory injury
32. Type I Interferon Controls Propagation of Long Interspersed Element-1.
33. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.